234 related articles for article (PubMed ID: 33624434)
1. TTN/OBSCN 'Double-Hit' predicts favourable prognosis, 'immune-hot' subtype and potentially better immunotherapeutic efficacy in colorectal cancer.
Liu Z; Wang L; Guo C; Liu L; Jiao D; Sun Z; Wu K; Zhao Y; Han X
J Cell Mol Med; 2021 Apr; 25(7):3239-3251. PubMed ID: 33624434
[TBL] [Abstract][Full Text] [Related]
2. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.
Domingo E; Freeman-Mills L; Rayner E; Glaire M; Briggs S; Vermeulen L; Fessler E; Medema JP; Boot A; Morreau H; van Wezel T; Liefers GJ; Lothe RA; Danielsen SA; Sveen A; Nesbakken A; Zlobec I; Lugli A; Koelzer VH; Berger MD; Castellví-Bel S; Muñoz J; ; de Bruyn M; Nijman HW; Novelli M; Lawson K; Oukrif D; Frangou E; Dutton P; Tejpar S; Delorenzi M; Kerr R; Kerr D; Tomlinson I; Church DN
Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):207-216. PubMed ID: 28404093
[TBL] [Abstract][Full Text] [Related]
3. Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring
Wen L; Chen Z; Ji X; Fong WP; Shao Q; Ren C; Cai Y; Li B; Yuan Y; Wang D; Li Y
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793867
[TBL] [Abstract][Full Text] [Related]
4. High prevalence of unusual KRAS, NRAS, and BRAF mutations in POLE-hypermutated colorectal cancers.
Favre L; Cohen J; Calderaro J; Pécriaux A; Nguyen CT; Bourgoin R; Larnaudie L; Dupuy A; Ollier M; Lechapt E; Sloma I; Tournigand C; Rousseau B; Pujals A
Mol Oncol; 2022 Sep; 16(17):3055-3065. PubMed ID: 35624529
[TBL] [Abstract][Full Text] [Related]
5. DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity.
Castellucci E; He T; Goldstein DY; Halmos B; Chuy J
Oncologist; 2017 May; 22(5):497-502. PubMed ID: 28465371
[TBL] [Abstract][Full Text] [Related]
6. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
[TBL] [Abstract][Full Text] [Related]
7. POLE somatic mutations in advanced colorectal cancer.
Guerra J; Pinto C; Pinto D; Pinheiro M; Silva R; Peixoto A; Rocha P; Veiga I; Santos C; Santos R; Cabreira V; Lopes P; Henrique R; Teixeira MR
Cancer Med; 2017 Dec; 6(12):2966-2971. PubMed ID: 29072370
[TBL] [Abstract][Full Text] [Related]
8. Ultra-mutated colorectal cancer patients with POLE driver mutations exhibit distinct clinical patterns.
Hu H; Cai W; Wu D; Hu W; Dong Wang L; Mao J; Zheng S; Ge W
Cancer Med; 2021 Jan; 10(1):135-142. PubMed ID: 33125191
[TBL] [Abstract][Full Text] [Related]
9. The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy.
Ahn SM; Ansari AA; Kim J; Kim D; Chun SM; Kim J; Kim TW; Park I; Yu CS; Jang SJ
Oncotarget; 2016 Oct; 7(42):68638-68649. PubMed ID: 27612425
[TBL] [Abstract][Full Text] [Related]
10. High mutational burden in colorectal carcinomas with monoallelic POLE mutations: absence of allelic loss and gene promoter methylation.
Hühns M; Nürnberg S; Kandashwamy KK; Maletzki C; Bauer P; Prall F
Mod Pathol; 2020 Jun; 33(6):1220-1231. PubMed ID: 31857678
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.
Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640
[TBL] [Abstract][Full Text] [Related]
12. The role of immune checkpoint inhibitors for patients with advanced stage microsatellite stable colorectal cancer and high tumor mutation burden: quantity or quality?
Vegivinti CTR; Gonzales Gomez C; Syed M; Ferrell M; Cheng S; Singhi A; Saeed A; Sahin IH
Expert Opin Biol Ther; 2023; 23(7):595-601. PubMed ID: 37318031
[TBL] [Abstract][Full Text] [Related]
13. Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer.
Lin A; Zhang H; Hu X; Chen X; Wu G; Luo P; Zhang J
Pharmacol Res; 2020 Sep; 159():105028. PubMed ID: 32569820
[TBL] [Abstract][Full Text] [Related]
14. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M
Front Immunol; 2021; 12():751407. PubMed ID: 34659255
[TBL] [Abstract][Full Text] [Related]
15. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
Picard E; Verschoor CP; Ma GW; Pawelec G
Front Immunol; 2020; 11():369. PubMed ID: 32210966
[TBL] [Abstract][Full Text] [Related]
16. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
17. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
18. Tumor mutational burden in colorectal cancer: Implications for treatment.
Marques A; Cavaco P; Torre C; Sepodes B; Rocha J
Crit Rev Oncol Hematol; 2024 May; 197():104342. PubMed ID: 38614266
[TBL] [Abstract][Full Text] [Related]
19. PD-1/PD-L1 immune checkpoint blockade-based combinational treatment: Immunotherapeutic amplification strategies against colorectal cancer.
Chen Y; Liu C; Zhu S; Liang X; Zhang Q; Luo X; Yuan L; Song L
Int Immunopharmacol; 2021 Jul; 96():107607. PubMed ID: 33831809
[TBL] [Abstract][Full Text] [Related]
20. PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients.
Wang Y; Chen H; Jiao X; Wu L; Yang Y; Zhang J; Wu L; Liu C; Zhuo N; Li S; Gong J; Li J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Li J; Li Y; Lu Z; Zhang H; Shen L
Cancer Immunol Immunother; 2022 Jan; 71(1):111-120. PubMed ID: 34028566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
